GB0110430D0 - Protein variants and uses thereof - Google Patents

Protein variants and uses thereof

Info

Publication number
GB0110430D0
GB0110430D0 GBGB0110430.6A GB0110430A GB0110430D0 GB 0110430 D0 GB0110430 D0 GB 0110430D0 GB 0110430 A GB0110430 A GB 0110430A GB 0110430 D0 GB0110430 D0 GB 0110430D0
Authority
GB
United Kingdom
Prior art keywords
variants
agonists
hgf
protein variants
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0110430.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0110430.6A priority Critical patent/GB0110430D0/en
Publication of GB0110430D0 publication Critical patent/GB0110430D0/en
Priority to CA2440775A priority patent/CA2440775C/en
Priority to AU2002251337A priority patent/AU2002251337B2/en
Priority to EP02720271A priority patent/EP1381681B1/en
Priority to DE60221510T priority patent/DE60221510T2/de
Priority to US10/475,616 priority patent/US7179786B2/en
Priority to DK02720271T priority patent/DK1381681T3/da
Priority to PCT/GB2002/001941 priority patent/WO2002088354A1/en
Priority to AT02720271T priority patent/ATE368741T1/de
Priority to ES02720271T priority patent/ES2291460T3/es
Priority to JP2002585635A priority patent/JP4637452B2/ja
Priority to US11/627,761 priority patent/US7795214B2/en
Priority to US12/858,189 priority patent/US8232258B2/en
Priority to JP2010208693A priority patent/JP2011045370A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
GBGB0110430.6A 2001-04-27 2001-04-27 Protein variants and uses thereof Ceased GB0110430D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0110430.6A GB0110430D0 (en) 2001-04-27 2001-04-27 Protein variants and uses thereof
JP2002585635A JP4637452B2 (ja) 2001-04-27 2002-04-29 肝細胞増殖因子／細胞分散因子（ｈｇｆ／ｓｆ）のｎｋ１断片およびそれらの変異体、ならびにそれらの使用
DK02720271T DK1381681T3 (da) 2001-04-27 2002-04-29 NK1-fragmentet af hepatocytvækstfaktor/spredningsfaktor (HGF/SF) og varianter deraf og deres anvendelser
AT02720271T ATE368741T1 (de) 2001-04-27 2002-04-29 Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung
EP02720271A EP1381681B1 (en) 2001-04-27 2002-04-29 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
DE60221510T DE60221510T2 (de) 2001-04-27 2002-04-29 Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung
US10/475,616 US7179786B2 (en) 2001-04-27 2002-04-29 Variants of the NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and their use
CA2440775A CA2440775C (en) 2001-04-27 2002-04-29 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
PCT/GB2002/001941 WO2002088354A1 (en) 2001-04-27 2002-04-29 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
AU2002251337A AU2002251337B2 (en) 2001-04-27 2002-04-29 The NK1 fragment of hepatocyte growth factors/scatter factor (HGF/SF) and variants thereof, and their use
ES02720271T ES2291460T3 (es) 2001-04-27 2002-04-29 Fragmento nk1 del factor de crecimiento de hepatocito/factor de dispersion (hgf/sf) y variantes de los mismos y su utilizacion.
US11/627,761 US7795214B2 (en) 2001-04-27 2007-01-26 Variants of the NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and their use
US12/858,189 US8232258B2 (en) 2001-04-27 2010-08-17 NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and variants thereof, and their use
JP2010208693A JP2011045370A (ja) 2001-04-27 2010-09-17 肝細胞増殖因子／細胞分散因子（ｈｇｆ／ｓｆ）のｎｋ１断片およびそれらの変異体、ならびにそれらの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0110430.6A GB0110430D0 (en) 2001-04-27 2001-04-27 Protein variants and uses thereof

Publications (1)

Publication Number Publication Date
GB0110430D0 true GB0110430D0 (en) 2001-06-20

Family

ID=9913640

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0110430.6A Ceased GB0110430D0 (en) 2001-04-27 2001-04-27 Protein variants and uses thereof

Country Status (11)

Country Link
US (3) US7179786B2 (enExample)
EP (1) EP1381681B1 (enExample)
JP (2) JP4637452B2 (enExample)
AT (1) ATE368741T1 (enExample)
AU (1) AU2002251337B2 (enExample)
CA (1) CA2440775C (enExample)
DE (1) DE60221510T2 (enExample)
DK (1) DK1381681T3 (enExample)
ES (1) ES2291460T3 (enExample)
GB (1) GB0110430D0 (enExample)
WO (1) WO2002088354A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20050107296A1 (en) * 2001-10-31 2005-05-19 Institut Des Vaisseaux Et Du Sang Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
US7563570B2 (en) 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US20090215686A1 (en) * 2007-03-05 2009-08-27 Huaqiang Eric Xu Nk1-based polypeptides and related methods
AU2008323719B2 (en) * 2007-11-09 2013-04-04 New York Medical College Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
WO2011103382A2 (en) * 2010-02-22 2011-08-25 The Brigham And Women's Hospital Compositions and methods for inducing angiogenesis
WO2011116396A2 (en) * 2010-03-19 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
AU2011326164B2 (en) 2010-11-08 2016-05-05 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013037520A1 (en) 2011-09-16 2013-03-21 Glaxo Group Limited Modified hgf-1k1 polypeptide
WO2013037521A1 (en) 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
CA2973300C (en) * 2015-01-21 2024-03-19 Universite Des Sciences Et Technologies De Lille-Lille 1 Met receptor agonist proteins
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN119613527A (zh) * 2024-12-30 2025-03-14 江苏三仪生物工程有限公司 鸡肝细胞生长因子的截短突变体及其在防治肝脏相关疾病方面的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594115A (en) * 1990-04-09 1997-01-14 Pharmacia & Upjohn Company Process of purifying recombinant proteins and compounds useful in such process
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
PT642580E (pt) 1992-05-18 2003-01-31 Genentech Inc Variantes de factor de crescimento dos hepatocitos
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof

Also Published As

Publication number Publication date
CA2440775A1 (en) 2002-11-07
US20040236073A1 (en) 2004-11-25
CA2440775C (en) 2013-02-26
US8232258B2 (en) 2012-07-31
DE60221510T2 (de) 2008-04-17
DK1381681T3 (da) 2007-10-29
US7179786B2 (en) 2007-02-20
DE60221510D1 (de) 2007-09-13
ATE368741T1 (de) 2007-08-15
EP1381681A1 (en) 2004-01-21
JP2011045370A (ja) 2011-03-10
JP2004532032A (ja) 2004-10-21
US20110021612A1 (en) 2011-01-27
AU2002251337B2 (en) 2007-08-02
JP4637452B2 (ja) 2011-02-23
US20080167224A1 (en) 2008-07-10
ES2291460T3 (es) 2008-03-01
US7795214B2 (en) 2010-09-14
EP1381681B1 (en) 2007-08-01
WO2002088354A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
GB0110430D0 (en) Protein variants and uses thereof
DE69916591T2 (de) Hochzähe, hochfeste amorphe zirkoniumlegierung
CY1108547T1 (el) Αναλογα σωματοστατινης
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
EP1217970A4 (en) IMPROVED TISSUE INJECTABLE MIXTURE
HUP0203506A3 (en) Modified peptides as therapeutic agents
MXPA02010787A (es) Peptidos modificados como agentes terapeuticos.
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
FI991485L (fi) Uusi farmaseuttinen koostumus
EE200300307A (et) 1,5-bensotiasepiinid ja nende kasutamine antilipideemiliste vahenditena
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
DE60038922D1 (de) Zusammensetzungen für den wiederaufbau von knochengewebe
DE69732309D1 (de) Primerzusammensetzungen für den Dentalbereich
DE60120712D1 (en) Kallikrein gen
NO20005668D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
PL372605A1 (en) Preparations containing at least one diformate
DE60036959D1 (de) Tensidzusammensetzungen, verbesserungsmittel enthaltend
HUP0203275A3 (en) 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants
PL370162A1 (en) Orodispersible pharmaceutical composition comprising perindopril
DE69933057D1 (de) Analoge des humanen basischen fibroblasten-wachstumsfactors
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
WO2004041296A3 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
NO20021614D0 (no) DNA kodende for PROST 07-polypeptid
EP1569677A4 (en) LIPOSOMAL COMPOSITION COMPRISING HAPTOTACTIC PEPTIDES

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)